LDL-C, ApoB and Lp(a): what does each test actually show?
Three related measurements. Three different clinical questions. None should be interpreted in isolation.
The quick answer
Cholesterol cargo, particle number, and inherited risk are not the same thing.
LDL-C estimates how much cholesterol is carried within the LDL fraction. ApoB estimates how many atherogenic particles are circulating. Lp(a) measures a specific, largely inherited LDL-like particle that adds risk beyond the standard lipid panel. Most people begin with a standard lipid profile; ApoB becomes especially informative when particle number may be underestimated by LDL-C, while Lp(a) is generally a once-in-adulthood risk test.
LDL-C — the cargo
Reports the concentration of cholesterol carried in LDL-related particles. It remains the principal screening and treatment target in current Brazilian and U.S. guidelines.
ApoB — the particle count
Each LDL, IDL, VLDL-remnant and Lp(a) particle carries one ApoB molecule. ApoB therefore estimates the total number of circulating atherogenic particles.
Lp(a) — the inherited signal
Measures one specific ApoB-containing particle linked to apolipoprotein(a). Its concentration is more than 90% genetically determined and usually changes little with lifestyle.
The core distinctionLDL-C asks how much cholesterol is being carried. ApoB asks how many atherogenic particles are carrying it. Lp(a) asks how much inherited particle-related risk is present.
Side by side
One blood draw can answer three different questions.
MERHI ONE Evidence Map
What the evidence supports—and what it does not.
Each rating applies to the exact statement shown. A strong biological association is not automatically proof that every test should be ordered for everyone or that every way of changing the number improves outcomes.
ApoB-containing lipoproteins, including LDL, play a causal role in atherosclerotic cardiovascular disease.2,4,5
Converging genetic, epidemiologic, mechanistic, and randomized-treatment evidence supports causality. The clinical effect of therapy still depends on the intervention, the amount and duration of reduction, and baseline absolute risk.
Lowering LDL-C with proven therapies reduces major vascular events.2,4
In the Cholesterol Treatment Trialists’ meta-analysis, each 1 mmol/L (about 38.7 mg/dL) reduction in LDL-C was associated with a roughly one-fifth proportional reduction in major vascular events. Absolute benefit is larger when baseline cardiovascular risk is higher.
ApoB estimates atherogenic particle number more directly than LDL-C.1,8
There is one ApoB molecule on each major atherogenic particle. LDL-C measures cholesterol mass, which can vary from particle to particle; the two markers therefore sometimes disagree.
ApoB is especially useful with high triglycerides, diabetes, obesity, metabolic or cardiovascular-kidney-metabolic disease, or known ASCVD.1,2,3
The 2025 Brazilian guideline gives a strong recommendation with moderate certainty for ApoB to assist risk assessment and therapy when triglycerides exceed 150 mg/dL. The 2026 U.S. guideline supports selective use to assess residual risk, including after LDL-C and non-HDL-C goals are reached.
Measure Lp(a) at least once in adulthood when available.1,2,3,6,7
Brazilian 2025 and U.S. 2026 guidelines recommend at least one adult measurement. NLA and EAS guidance also support universal once-in-adulthood testing because the concentration is largely inherited and relatively stable.
Elevated Lp(a) is a causal risk factor for ASCVD and calcific aortic valve stenosis.6,7,9
Genetic and observational evidence supports a continuous association across ancestries. Elevated Lp(a) can matter even when LDL-C is otherwise well controlled.
Do not convert Lp(a) between mg/dL and nmol/L with one fixed factor.1,6,8,9
Apolipoprotein(a) varies in molecular size between people, so mass and particle concentration are not linked by a universal conversion. Brazilian and European guidance prefer an isoform-insensitive assay reported in nmol/L when available.
Lifestyle changes substantially lower the Lp(a) concentration itself.2,6,7,9
Diet, exercise, and weight management have major cardiovascular benefits but usually have minimal direct effect on genetically determined Lp(a) levels.
Lowering Lp(a) with a specific new drug has already been proven to prevent heart attacks or strokes.2,6,7
As of this scientific review, targeted antisense and siRNA therapies can markedly lower Lp(a), but definitive cardiovascular-outcome evidence is still awaited. Drugs must be judged by clinical outcomes, not biomarker change alone.
ApoB should replace LDL-C for every adult and every treatment decision.1,2,3
Current Brazilian and U.S. guidance retains LDL-C and non-HDL-C as primary targets while expanding selective ApoB use. For most people, the markers are highly correlated and provide similar information.
Two native pathways
The biology is shared. Targets and implementation differ by country.
United States — 2026 ACC/AHA
- Lp(a): measure at least once in adulthood; ≥125 nmol/L or ≥50 mg/dL is a risk-enhancing level.
- ApoB: selective use for residual risk in CKM syndrome, type 2 diabetes, high triglycerides, known ASCVD, or discordant results.
- LDL-C goals: <100 mg/dL for borderline/intermediate primary-prevention risk; <70 mg/dL for high risk; <55 mg/dL for very-high-risk ASCVD.
- PREVENT-ASCVD is the current guideline framework for eligible adults ages 30–79 without known ASCVD or subclinical disease and LDL-C 70–189 mg/dL.
Brazil — 2025 SBC
- Lp(a): measure once in the general adult population when available; recommendation strong, certainty moderate.
- Prefer isoform-independent measurement in nmol/L; do not use a fixed conversion from mg/dL.
- ApoB: may assist risk assessment when triglycerides are >150 mg/dL; non-HDL-C remains a practical, no-extra-cost alternative.
- LDL-C goals by risk: <115 low, <100 intermediate, <70 high, <50 very high, and <40 mg/dL extreme risk.
Reading combinations
When the numbers disagree, the pattern matters.
LDL-C high + ApoB high
Cholesterol burden and atherogenic particle number point in the same direction. The next step is to determine overall risk, secondary causes, family history, and the appropriate target.
LDL-C apparently acceptable + ApoB high
There may be more cholesterol-depleted atherogenic particles than LDL-C suggests. This pattern is more common with high triglycerides, diabetes, obesity, insulin resistance, and metabolic syndrome.
LDL-C high + ApoB not elevated
Particles may be relatively cholesterol-rich. This does not automatically make elevated LDL-C harmless; guideline targets and the total risk assessment still apply.
Lp(a) high at any LDL-C or ApoB
Lp(a) adds inherited risk that can persist despite otherwise favorable numbers. Intensify control of modifiable risk factors and consider testing first-degree relatives.
All three favorable
This is reassuring for lipoprotein-related risk but does not exclude hypertension, diabetes, smoking risk, inflammation, kidney disease, or existing atherosclerosis.
Common interpretation errors
A sophisticated test can still be used badly.
The principal danger is turning a useful marker into a diagnosis, a guarantee, or a treatment plan by itself.
‘My LDL-C is normal, so my risk is zero’
LDL-C is one part of risk. ApoB discordance, elevated Lp(a), blood pressure, diabetes, kidney disease, smoking, family history, and established plaque can change the picture.
‘ApoB and Lp(a) are the same test’
Lp(a) is one specific ApoB-containing particle. ApoB counts the broader population of atherogenic particles; it does not reveal how much of that count is Lp(a).
‘High HDL-C cancels high LDL-C or ApoB’
HDL-C is a risk marker but has not been shown to neutralize exposure to atherogenic ApoB-containing particles.
‘A supplement can normalize inherited Lp(a)’
No supplement has proven that lowering Lp(a) through supplementation prevents cardiovascular events. Niacin can lower the number but is not recommended for this purpose because outcome benefit was not demonstrated.
‘I can convert any Lp(a) result online’
A fixed conversion between mg/dL and nmol/L is analytically unreliable because apo(a) particle size varies.
‘One result tells me which medication and dose to take’
Treatment requires absolute risk, prior disease, comorbidities, baseline values, response, adverse effects, preferences, and country-specific guidance.
What a wrong interpretation can cause
- False reassurance from one favorable marker
- Anxiety from inherited risk without context
- Unnecessary repeat Lp(a) testing
- Inappropriate supplements or self-medication
- Stopping effective therapy because Lp(a) did not fall
- Ignoring family screening when Lp(a) is high
A practical next step
Turn three numbers into one cardiovascular-risk conversation.
- 01
Start with a standard lipid profile and confirm the clinical context, fasting status if relevant, prior results, medications, and metabolic stability.
- 02
Estimate absolute cardiovascular risk and identify established ASCVD, diabetes, kidney disease, smoking, blood pressure, family history, and possible familial hypercholesterolemia.
- 03
Consider ApoB when triglycerides are elevated, LDL-C and non-HDL-C appear discordant, cardiometabolic risk is present, or residual risk could change management.
- 04
Measure Lp(a) at least once in adulthood; repeat only when a defined clinical or analytical reason exists.
- 05
If Lp(a) is high, intensify modifiable-risk management and discuss first-degree-relative testing rather than promising that lifestyle will normalize the marker.
- 06
Set the LDL-C/non-HDL-C—and, when appropriate, ApoB—goal according to the guideline and the individual’s risk, then monitor response at a clinically appropriate interval.
Frequently asked
Direct answers to the questions patients actually ask.
Which is better: LDL-C or ApoB?+
For routine care, LDL-C remains the main validated target. ApoB can be more informative when cholesterol content and particle number are discordant, especially with high triglycerides or cardiometabolic disease.
Is Lp(a) included in ApoB?+
An Lp(a) particle carries one ApoB molecule, so it contributes to total ApoB. However, an ApoB result cannot tell how much Lp(a) is present; Lp(a) requires its own assay.
Does Lp(a) require fasting?+
Usually no. Lp(a) is relatively stable and not meaningfully changed by an ordinary meal, although measurement should ideally occur in a stable clinical state and follow laboratory instructions.
How often should Lp(a) be repeated?+
Usually once in adulthood is sufficient. Repeat testing may be considered when the first result occurred during a condition that can alter it, the assay changed, kidney or liver status changed substantially, or a specific treatment is being monitored.
Can statins raise Lp(a)? Should they be stopped?+
Statins may leave Lp(a) unchanged or increase it slightly, but their proven cardiovascular benefit through LDL-C lowering generally outweighs that change. Do not stop prescribed therapy without medical review.
If my Lp(a) is high, should my family be tested?+
Current Brazilian, U.S., NLA, and EAS guidance supports cascade testing of first-degree relatives in families with elevated Lp(a), premature ASCVD, or related high-risk features.
Can I calculate my own target from this article?+
No. Targets differ by country and risk category. A personal decision requires clinical history, prior disease, comorbidities, medications, preferences, and confirmation of the laboratory context.
Claim-level foundation
References
Priority was given to current national guidelines, professional-society statements, laboratory guidance, and high-level evidence. Citations beside each claim point to the supporting sources.
- 01Open source ↗
Sociedade Brasileira de Cardiologia · 2025
Brazilian Guideline on Dyslipidemias and Prevention of Atherosclerosis
- 02Open source ↗
ACC / AHA / Multisociety · 2026
Guideline on the Management of Dyslipidemia
- 03Open source ↗
American College of Cardiology · 2026
How the 2026 Dyslipidemia Guideline Changes Practice
- 04Open source ↗
Cholesterol Treatment Trialists’ Collaboration · 2010
More intensive lowering of LDL cholesterol: meta-analysis of 170,000 participants
- 05Open source ↗
European Atherosclerosis Society · 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease
- 06Open source ↗
European Atherosclerosis Society · 2022
Lipoprotein(a) in ASCVD and aortic stenosis: consensus statement
- 07Open source ↗
National Lipid Association · 2024
Focused update on use of lipoprotein(a) in clinical practice
- 08Open source ↗
Association for Diagnostics & Laboratory Medicine · 2024; correction 2025
Guidance on measurement and reporting of lipids and lipoproteins
- 09Open source ↗
American College of Cardiology · 2023; reviewed 2026
Lipoprotein(a): testing, treatment, and guideline recommendations
Editorial record